Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R H Collins

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Blood|February 27, 2001
Factors affecting thymic function after allogeneic hematopoietic stem cell transplantationK Weinberg, B R Blazar, J E Wagner, et al.
Bone Marrow Transplantation|January 10, 2001
Donor leukocyte infusions for multiple myelomaM Salama, T Nevill, D Marcellus, et al.
Blood|April 15, 1996
FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantationJ W Fay, J R Wingard, J H Antin, et al.
Blood|February 9, 2000
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusionsD L Porter, R H Collins, C Hardy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantationR H Collins, O Shpilberg, W R Drobyski, et al.
Blood|August 15, 1996
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphomaM J Stone, E A Sausville, J W Fay, et al.
Leukemia & Lymphoma|October 8, 1999
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant GroupD R Fleming, S N Wolff, J W Fay, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Blood|February 27, 2001
Factors affecting thymic function after allogeneic hematopoietic stem cell transplantationK Weinberg, B R Blazar, J E Wagner, et al.
Bone Marrow Transplantation|January 10, 2001
Donor leukocyte infusions for multiple myelomaM Salama, T Nevill, D Marcellus, et al.
Blood|April 15, 1996
FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantationJ W Fay, J R Wingard, J H Antin, et al.
Blood|February 9, 2000
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusionsD L Porter, R H Collins, C Hardy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantationR H Collins, O Shpilberg, W R Drobyski, et al.
Blood|August 15, 1996
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphomaM J Stone, E A Sausville, J W Fay, et al.
Leukemia & Lymphoma|October 8, 1999
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant GroupD R Fleming, S N Wolff, J W Fay, et al.
Pageof 4